CITATION REPORT List of articles citing

Proteasome inhibitors

DOI: 10.1016/b978-0-12-397863-9.00005-5 Progress in Molecular Biology and Translational Science, 2012, 109, 161-226.

Source: https://exaly.com/paper-pdf/53915938/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
26	Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. <i>Cancer Research</i> , 2013 , 73, 4965-77	10.1	191
25	Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF- B . <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 304, H567-78	5.2	61
24	Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. <i>Gynecologic Oncology</i> , 2013 , 128, 383-90	4.9	34
23	Recent advancements of bortezomib in acute lymphocytic leukemia treatment. <i>Acta Haematologica</i> , 2013 , 129, 207-14	2.7	19
22	Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013 , 304, E87-99	6	57
21	Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action. <i>ChemBioChem</i> , 2014 , 15, 2125-31	3.8	21
20	Noncovalent fluorescent probes of human immuno- and constitutive proteasomes. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 9211-7	8.3	4
19	Diethyldithiocarbamate complexes with metals used as food supplements show different effects in cancer cells. <i>Journal of Applied Biomedicine</i> , 2014 , 12, 301-308	0.6	14
18	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 61-70	7	16
17	DNA damage emergency: cellular garbage disposal to the rescue?. Oncogene, 2014, 33, 805-13	9.2	15
16	The Tumor Microenvironment as a Target for Therapeutic Intervention. 2015 , 47-63		
15	Clinical use of proteasome inhibitors in the treatment of multiple myeloma. <i>Pharmaceuticals</i> , 2014 , 8, 1-20	5.2	53
14	Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 2036-41	8.3	35
13	Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1. <i>Cancer Biology and Therapy</i> , 2015 , 16, 780-9	4.6	9
12	Recent advances and novel treatment paradigms in acute lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 252-269	5.7	17
11	Mammalian proteasome subtypes: Their diversity in structure and function. <i>Archives of Biochemistry and Biophysics</i> , 2016 , 591, 132-40	4.1	57
10	Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017 , 128, 180-191	6.8	11

CITATION REPORT

9	Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. <i>Structure</i> , 2017 , 25, 1839-1855.e11	5.2	8	
8	Prevention of Streptozotocin-Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IB. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 3671751	6.7	10	
7	Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 207-228		1	
6	Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research. <i>Journal of Antibiotics</i> , 2019 , 72, 189-201	3.7	22	
5	Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents. <i>Molecular Biology Reports</i> , 2021 , 48, 3999-4008	2.8	1	
4	Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. <i>Molecular Medicine Reports</i> , 2019 , 19, 5023-5029	2.9	1	
3	Multiple deadlocks in the development of nonprofit drugs. Drug Discovery Today, 2022,	8.8		
2	PSMB2 knockdown suppressed proteasome activity and cell proliferation, promoted apoptosis, and blocked NRF1 activation in gastric cancer cells. <i>Cytotechnology</i> ,	2.2	О	
1	Memory B cells and long-lived plasma cells in AMR. 2022 , 44, 1604-1614		0	